ClinicalTrials.gg
Not yet recruitingNCT07939841NACxosUpdated Nov 16, 2026

N-Acetylcysteine (NAC) in Primary Sclerosing Cholangitis (PSC)

A Phase 2 interventional study of N-Acetylcysteine (NAC) Treatment in Primary Sclerosing Cholangitis (PSC), sponsored by Brigham and Women's Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 75 studies in Cholangitis, Sclerosing with a site in United States — 19 open to participants now, 22 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.

Planned enrollment
40th of 57
15 · median 27
Started
2026
with 3 others
Phase 2
26 of 75
6 open now
Primary completion
2028-07
later than 12 of 21 live
Registered
75th of 75
by date
Lead sponsor
5 of 75
Brigham and Women's Hospital

Among the 75 studies in Cholangitis, Sclerosing with a site in United States, this one is the 40th largest by planned enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2026, is one of 26 in phase 2, reaches primary completion later than 12 of the 21 other live ones, and was the 75th registered.

Cholangitis, Sclerosing

150 studies on the registry are indexed under Cholangitis, Sclerosing; 39 are open to participants now.

Browse Cholangitis, Sclerosing studies →

Open to participants now

19 of the 75 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Cholangitis, Sclerosing with a site in United States, or all of them as a file.
02

Study summary

Primary sclerosing cholangitis (PSC) is a chronic disease that causes inflammation and scarring of the bile ducts and can lead to progressive liver damage. There are currently no approved medications that have been shown to improve long-term outcomes in patients with PSC.

The purpose of this pilot study is to evaluate whether N-acetylcysteine (NAC), a medication that helps the body produce an antioxidant called glutathione, may improve liver blood tests in people with PSC.

This is a single-center, open-label study involving approximately 15 adults with PSC. All participants will receive oral NAC at a dose of 1,200 mg per day for the first 12 weeks. At Week 12, the dose will either remain the same or increase to 1,800 mg per day, depending on changes in a liver blood test called alkaline phosphatase (ALP).

Participants will continue treatment through Week 16. Those with a substantial improvement in ALP may be eligible to continue treatment through Week 20.

Researchers will evaluate changes in liver blood tests, treatment safety, side effects, and medication adherence. Additional blood tests may help researchers better understand how NAC affects liver injury.

This study is intended to provide preliminary information about the potential benefits and safety of NAC in PSC. It is not designed to establish whether NAC is an effective treatment for PSC.

Read the detailed description

This is a prospective, single-center, open-label, single-arm, response-adaptive pilot study designed to assess the biochemical effects, safety, and tolerability of oral N-acetylcysteine (NAC) monotherapy in adults with primary sclerosing cholangitis (PSC).

The study will enroll approximately 15 participants at Brigham and Women's Hospital.

All enrolled participants will receive NAC 600 mg orally twice daily (1,200 mg/day) for the first 12 weeks. At Week 12, participants with a reduction in serum alkaline phosphatase (ALP) of at least 40% from baseline will continue receiving 1,200 mg/day. Participants with less than a 40% reduction will increase their total daily dose to 1,800 mg for Weeks 12 through 16.

The primary outcome is the percentage change in serum ALP from baseline to Week 16.

Secondary assessments include changes in ALP at Week 12, biochemical response rates, changes in other liver enzymes (AST, ALT, and GGT), adverse events, treatment tolerability, adherence, and feasibility.

Exploratory assessments will include blood-based biomarkers associated with liver injury and fibrosis, including PRO-C3 and GDF-15.

Study assessments will occur at screening, baseline, and Weeks 4, 8, 12, and 16. Participants who achieve at least a 50% reduction in ALP at Week 16 may be eligible for an optional treatment extension through Week 20, with additional follow-up assessment.

There is no randomization, placebo group, or active comparator. This exploratory study is designed to generate preliminary evidence regarding the biochemical response to NAC monotherapy and inform the design of future controlled clinical trials.

03

Conditions studied

  • Primary Sclerosing Cholangitis (PSC)

Keywords

  • N-Acetylcysteine
  • NAC
  • Primary Sclerosing Cholangitis
  • Alkaline Phosphatase
  • Glutathione
  • Liver Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

**Inclusion Criteria:**

  • Adults aged 18 to 70 years.
  • Diagnosis of primary sclerosing cholangitis (PSC) for at least 6 months, confirmed by characteristic cholangiographic findings, without evidence of secondary sclerosing cholangitis.
  • Serum alkaline phosphatase (ALP) greater than 1.33 times the at screening.
  • count greater than 150,000/mm³, serum albumin greater than 3.3 g/dL, and serum creatinine below the upper limit of normal.
  • For participants receiving ursodeoxycholic acid (UDCA), a stable dose for at least 3 months before screening. Participants not receiving UDCA must have been off UDCA for at least 3 months.
  • For participants receiving mesalamine, sulfasalazine, immunomodulators, or biologic medications for inflammatory bowel disease, a stable dose for at least 4-8 weeks before enrollment, with no planned treatment changes during the study.
  • For participants receiving oral , a daily dose not exceeding 20 mg of prednisone or 6 mg of budesonide at enrollment.
  • Willingness and ability to provide and comply with study visits, medication administration, and laboratory testing.
  • No concurrent enrollment in another interventional PSC trial.

**Exclusion Criteria:**

  • Pregnancy or breastfeeding.
  • Known to N-acetylcysteine (NAC) or any component of the study capsules.
  • (ALT) greater than 10 times the upper limit of normal, total greater than 2 times the upper limit of normal (except in participants with Gilbert syndrome), or (INR) greater than 1.2.
  • Decompensated cirrhosis, including ascites, hepatic encephalopathy, or variceal bleeding.
  • Small-duct primary sclerosing cholangitis.
  • Other causes of liver disease, including secondary sclerosing cholangitis, viral liver disease, alcohol-related liver disease, or other liver diseases, including positive antimitochondrial antibodies. Participants with nonalcoholic fatty liver disease may be eligible if there is no evidence of nonalcoholic steatohepatitis.
  • History of liver transplantation, hepatocellular carcinoma, or cholangiocarcinoma.
  • Ascending cholangitis within 90 days before enrollment.
  • Severe ulcerative colitis flare requiring intravenous corticosteroids within 3 weeks before enrollment, or an anticipated change to a new inflammatory bowel disease medication within 3 months.
  • Concurrent participation in another therapeutic clinical trial.
  • Any laboratory abnormality or medical condition that, in the investigator's judgment, could compromise participant safety or interfere with the evaluation of study outcomes.
  • Current regular use of an NAC-containing supplement outside the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    N-Acetylcysteine (NAC) Treatment

    Participants will receive oral N-acetylcysteine (NAC) at a dose of 600 mg twice daily (1,200 mg/day) for the first 12 weeks. At Week 12, participants with a reduction in alkaline phosphatase (ALP) of at least 40% from baseline will continue at 1,200 mg/day, while those with less than a 40% reduction will increase to 1,800 mg/day through Week 16. Participants achieving at least a 50% reduction in ALP at Week 16 may continue treatment through Week 20, according to the study protocol.

    Drug: N-Acetylcysteine (NAC) Treatment

Interventions

  • N-Acetylcysteine (NAC) will be administered orally at a dose of 600 mg twice daily (1,200 mg/day) for the first 12 weeks. At Week 12, participants with a reduction in serum alkaline phosphatase (ALP) of at least 40% from baseline will continue receiving 1,200 mg/day, while those with less than a 40% reduction will increase to 1,800 mg/day for Weeks 12-16. Participants achieving at least a 50% reduction in ALP at Week 16 may continue NAC treatment through Week 20, according to the protocol. The intervention will be administered as oral 600 mg capsules.

06

What researchers measure

Primary outcomes

  1. Percentage Change in Serum Alkaline Phosphatase (ALP)

    Percentage change in serum alkaline phosphatase (ALP) from baseline to Week 16, calculated as \[(Week 16 ALP - baseline ALP) / baseline ALP\] × 100. ALP will be measured using standard clinical laboratory testing. Negative percentage changes indicate a reduction in ALP.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Longitudinal Change in Aspartate Aminotransferase (AST)

    Changes in serum AST from baseline will be assessed at Weeks 12 and 16. Absolute changes will be expressed in U/L.

    Time frame: Baseline, Week 12, and Week 16

  2. Longitudinal Change in Alanine Aminotransferase (ALT)

    Changes in serum ALT from baseline will be assessed at Weeks 12 and 16. Absolute changes will be expressed in U/L.

    Time frame: Baseline, Week 12, and Week 16

  3. Longitudinal Change in Gamma-Glutamyl Transferase (GGT)

    Changes in serum GGT from baseline will be assessed at Weeks 12 and 16. Absolute changes will be expressed in U/L.

    Time frame: Baseline, Week 12, and Week 16

Other outcomes

  1. Change in Serum Biomarkers (PRO-C3 and GDF-15)

    Changes in serum PRO-C3 and GDF-15 concentrations during NAC treatment, assessed separately as exploratory markers of liver fibrosis and cellular stress.

    Time frame: Baseline, Week 8, and Week 16 (PRO-C3); Baseline and Week 16 (GDF-15).

07

Study locations

1 site
08

References and documents

Publications

  • Ozdil B, Cosar A, Akkiz H, Sandikci M, Kece C. New therapeutic option with N-acetylcysteine for primary sclerosing cholangitis: two case reports. Am J Ther. 2011 May;18(3):e71-4. doi: 10.1097/MJT.0b013e3181c42758. PubMed 20019586 ↗
  • Har-Zahav A, Tobar A, Fried S, Sivan R, Wilkins BJ, Russo P, Shamir R, Wells RG, Gurevich M, Waisbourd-Zinman O. Oral N-acetylcysteine ameliorates liver fibrosis and enhances regenerative responses in Mdr2 knockout mice. Sci Rep. 2024 Nov 3;14(1):26513. doi: 10.1038/s41598-024-78387-2. PubMed 39489865 ↗

Individual participant data

Plan to share: No — There is currently no plan to share individual participant-level data with researchers outside the study team. Study data will be maintained securely in accordance with Mass General Brigham policies and the approved research protocol. Any future data sharing would be subject to applicable institutional and regulatory approvals.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2028, 18 months later.

Of 23 phase 2 interventional studies under Cholangitis, Sclerosing, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 62. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Dec 5, 2026
Primary completionEst.
Jul 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939841
Responsible party
Joshua Korzenik (Resnek Family Distinguished Chair in Gastroenterology and Hepatology, Brigham and Women's Hospital) — Principal investigator
First posted
Nov 16, 2026
Start date
Dec 5, 2026 (estimated)
Primary completion
Jul 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Omid yazdani, MD
Contact
oyazdani@bwh.harvard.edu
6178630706
Joshua Korzenik, MD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetylcysteine

Start the discussion